BTIG analyst David Larsen downgraded Definitive Healthcare (DH) to Neutral from Buy and removed the firm’s price target. While were encouraged to hear management say on the call that churn is starting to stabilize, declines in revenue and client losses still seem to be material headwinds and it is unclear when top-line growth will rebound given that the bio-pharma market is facing pricing headwinds, the risk of tariffs, a more challenging fund-raising environment, the analyst tells investors. The firm also believes that Veeva (VEEV), Iqvia (IQV) and Doximity (DOCS) are “all very competitive,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Definitive Healthcare Corp: Hold Rating Amid Positive Developments and Market Challenges
- Definitive Healthcare Reports Q1 2025 Financial Results
- Definitive Healthcare sees Q2 EPS 4c-5c, consensus 5c
- Definitive Healthcare sees FY25 adjusted EPS 20c-23c, consensus 21c
- Definitive Healthcare reports Q1 adjusted EPS 5c, consensus 2c
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue